{
    "nct_id": "NCT02962414",
    "official_title": "An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.",
    "inclusion_criteria": "* Patient is currently enrolled in the Novartis-sponsored EXIST-3 study, receiving everolimus, and has fulfilled all its requirements\n* Patient is currently benefiting from treatment with everolimus, as determined by the Investigator.\n* Patient has demonstrated compliance, as assessed by the Investigator,with the parent study protocol requirements.\n* Patient is willing and able to comply with scheduled visits and treatment plans.\n* Written informed consent/adolescent assent obtained prior to enrolling into the roll-over study.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Patient has been permanently discontinued from everolimus study treatment in EXIST-3 study\n* Everolimus is approved for patients with TSC and refractory seizures and is reimbursed in the local country.\n* Patients who are receiving everolimus in combination with unapproved or experimental treatments for seizure control Anti-epileptic drug (AEDs) are allowed for the purpose of seizure control.",
    "miscellaneous_criteria": "Key"
}